Gilead Sciences (GILD)

Warning! As of 20 September 2021, the EU lobby register has changed format. Temporarily, the register is no longer providing daily data updates of all lobby data which means that the figures on LobbyFacts cannot currently be kept up-to-date. If, for example, you see a company, trade association, or lobby consultancy with "no figure available" for EU lobby costs, open the data card, and click the link to the EU lobby register where you will find the updated registration including EU lobby costs declaration. Regretably, under the lobby register format, NGOs and think tanks are no longer required to provide a figure for EU lobby costs. We will update LobbyFacts with the new data as soon as possible.

Tweet this page
How to read and use this data card.

Lobbying costs:

WARNING: As this organisation lists one or more EP accredited lobbyists, it is highly improbable that its lobbying costs are lower than €10,000.

WARNING: The lobbying costs declared by this organisation are extraordinarily high and may therefore have been over-declared.

700,000€ - 799,999€

Financial year: 01/01/2020 - 01/12/2020

Lobbyists declared: 1.5 FTE (2)

WARNING: The number of full time equivalent lobbyists declared by this organisation are extraordinarily high and may therefore have been over-declared.


Lobbyists with EP accreditation: 0

Meetings with European Commission: 10

Lobbying costs over the years:


Gilead Sciences (GILD)

Registration on EU Transparency Register

258845020786-10 (First registered: 23 Feb 2016)

Goals / Remit

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 38 countries worldwide.


EU initiatives relevant to HIV/AIDS, Hepatitis B & C and oncology - ATMP Regulation - EU IP policy - EU research policy - EU trade policy - Health Systems Performance Assessment - Health Technology Assessment & Market Access - Industrial policy - Outcomes-based healthcare systems - Orphan Medicinal Products Regulation - Paediatric Regulation - Digital Health - Europe's Beating Cancer Plan - Blood, tissues and cells legislation - Sustainable Development Goals - EC Pharma Strategy - European Health Union - EU4Health


Head office:
333 Lakeside Foster City Foster City
California CA94404
United States

Tel: 1 6505743000

Belgium office:
Park Lane Culliganlaan 2 Culliganlaan 2
Diegem 1831,

Tel: 32 24 01 35 50